For instance, myristol-CM4, a new synthetic analog of AMP CM4, exerts its antitumor capacity against breast cancer cells by targeting mitochondria, which leads to a release of pro-apoptotic factors such as cytochrome C and induces mitochondria-dependent apoptosis [34]. This evidence concerns the gene CYCS and breast carcinoma.